Current treatment strategies for inflammatory bowel disease patients at the risk of developing cancer: a comprehensive review
J. coloproctol. (Rio J., Impr.)
;
43(3): 227-234, July-sept. 2023. tab, ilus
Artículo
en Inglés
| LILACS
| ID: biblio-1521140
ABSTRACT
Inflammatory bowel disease (IBD) is a chronic condition that affects the digestive tract and can lead to inflammation and damage to the intestinal lining. IBD patients with cancer encounter difficulties since cancer treatment weakens their immune systems. A multidisciplinary strategy that strikes a balance between the requirement to manage IBD symptoms and the potential effects of treatment on cancer is necessary for effective care of IBD in cancer patients. To reduce inflammation and avoid problems, IBD in cancer patients is often managed by closely monitoring IBD symptoms in conjunction with the necessary medication and surgical intervention. Anti-inflammatory medications, immunomodulators, and biologic therapies may be used for medical care, and surgical options may include resection of the diseased intestine or removal of the entire colon. The current study provides a paradigm for shared decision-making involving the patient, gastroenterologist, and oncologist while considering recent findings on the safety of IBD medicines, cancer, and recurrent cancer risk in individuals with IBD. We hope to summarize the pertinent research in this review and offer useful advice. (AU)
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Enfermedades Inflamatorias del Intestino
/
Neoplasias del Cuello Uterino
/
Neoplasias Urológicas
/
Neoplasias Gastrointestinales
Límite:
Humanos
Idioma:
Inglés
Revista:
J. coloproctol. (Rio J., Impr.)
Asunto de la revista:
Cirurgia
/
Doenas Retais
/
Doenas do Colo
/
Gastroenterologia
/
Cirurgia
Año:
2023
Tipo del documento:
Artículo
País de afiliación:
India
Institución/País de afiliación:
Ramaiah University of Applied Sciences/IN
Similares
MEDLINE
...
LILACS
LIS